Compare Charles River Laboratories Intl. Inc (CRL) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs MakeMyTrip Ltd — how do they compare? Charles River Laboratories Intl. Inc trades at $225.97 (market cap $11.14B), while MakeMyTrip Ltd trades at $55.72 (market cap $5.29B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.1× MakeMyTrip Ltd's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals.
| CRL | MMYT | |
|---|---|---|
Market Cap | $11.14B | $5.29B |
Sector | Health | Technology |
52-Week High | $233.60 | $103.21 |
52-Week Low | $145.57 | $36.30 |
Enterprise Value | $14.00B | $5.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
MakeMyTrip (MMYT) trades at $57.08, down 2.63% today but maintains a bullish technical outlook with strong analyst support. The company demonstrates robust fundamentals with $978M revenue and $95M net income for 2025, though 2026 projections show margin compression. Recent earnings beats and a 73% gross margin highlight operational strength, while technical indicators show bullish moving averages despite recent price weakness.
The stock presents a compelling growth opportunity with strong analyst consensus (73% buy ratings) and consistent earnings outperformance. However, elevated P/E ratio (154.86) and projected margin pressure in 2026 warrant caution. Key risks include travel industry volatility and rising debt-to-asset ratio from 12% to 81% projected for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
